肺炎衣原体感染的冠心病患者C-反应蛋白检测及意义被引量：5

Detection of C-reactive protein in patients with coronary heart disease with pulmonary Chlamydiainfections and its significance

原文传递

导出

摘要目的比较并探讨肺炎衣原体感染的冠心病患者C-反应蛋白(CRP)的水平变化。方法收集医院2009年1月-2011年2月确诊的105例肺炎衣原体感染的冠心病患者为感染组,并以同期入院治疗的108例普通冠心病患者为对照组,检测并比较不同组别治疗前后的CRP水平。结果治疗前对照组稳定性心绞痛、不稳定性心绞痛、急性心肌梗死的CRP分别为(1.19±0.75、3.44±0.81、5.56±0.64)mg/L,感染组分别为(6.98±1.54、14.97±3.57、38.77±4.01)mg/L,两组比较,差异有统计学意义;经治疗后,对照组稳定性心绞痛、不稳定性心绞痛、急性心肌梗死的CRP分别为(0.85±0.53、2.11±0.71、4.02±0.51)mg/L,感染组分别为(2.34±1.15、5.61±2.19、8.56±3.18)mg/L,两个组别的CRP水平均显著低于治疗前(P<0.05);感染组不同血管病变组的CRP水平显著高于对照组(P<0.05);经治疗后,两个组别的CRP水平均显著降低(P<0.05)。结论 CRP水平与肺炎衣原体感染冠心病的进展及预后紧密相关,可用于预测肺炎衣原体感染冠心病的进展阶段。 OBJECTIVE To compare and explore the change of C-reactive protein level in patients with coronary heart disease and lung chlamydia infection.METHODS From Jan.2009 to Feb.2011,a total of 105 cases of diagnosed coronary heart disease with lung chlamydia infections were collected and analyzed.At the same period,108 hospitalized patients with normal coronary heart disease but without infections were enrolled as control group.The levels of C-reactive protein between the two groups before and after treatment were compared.RESULTS Before the treatment,CRP level of the patients with SAP in the infection and control group was（1.19 ± 0.75 mg/L vs.6.98±1.54 mg/L）,of the patients with UAP was（3.44±0.81 mg/L vs.14.97±3.57 mg/L）,of the patients with AMI was（5.56±0.64 mg/L vs.38.77±4.01 mg/L）,the differences were statistically significant;after the treatment,the CRP levels of patients with SAP in both groups were（0.85±0.53 mg/L vs.2.34±1.15 mg/L,P〈0.05）,of the patients with UAP were（2.11±0.71 mg/L vs.5.61±2.19 mg/L,P〈0.05）,and of the patients with AMI was（4.02±0.51 mg/L vs.8.56±3.18mg/L,P〈0.05）.The levels of CRP of the two groups after treatment was significantly lower than those before treatment.CONCLUSION The level of CRP is closely associated with the progress,prognosis of coronary heart disease in patients with pulmonary chlamydia infections,which can be used to predict the advanced stage of coronary heart disease with lung chlamydia infections.

作者方裕

机构地区宁波市鄞州人民医院心血管科

出处《中华医院感染学杂志》 CAS CSCD 北大核心 2012年第8期1616-1618,共3页 Chinese Journal of Nosocomiology

关键词肺炎衣原体冠心病 C-反应蛋白 Chlamydia pneumoniae Coronary heart disease C-reactive protein

分类号 R181.32 [医药卫生—流行病学]

引文网络
相关文献

参考文献5

1Hilden J,Lind I,Kolmos HJ. Chlamydia pneumoniae IgG and IgA antibody titers and prognosis in patients with coronary heart disease:results from the CLARICOR trial[J].Diagnostic Microbiology and Infectious Disease,2010,(04):385-392.
2Stassen FR,Vainas T,Bruggeman CA. Infect ionand atherosclerosis An alternative view on an outdated hypothesis[J].PHARMACOLOGICAL REPORTS,2008,(01):85-92.
3Ikeoka DT,Vieira CZ. Lemos PA Azithromycin does not prevent six-month myointimal proliferation but attenuates the transient systemic inflammation occurring after coronary stenting[J].CLINICAL RESEARCH IN CARDIOLOGY,2009,(01):44-51.
4Kones R. Primary prevention of coronary heart disease:integration of new data,evolving views,revised goals,and role of rosuvastatin in management.A comprehensive survey[J].Drug Des Devel Ther,2011,(01):325-380.
5Emberson J,Bennett D,Link E. C-reactive protein concentration and the vascular benefits of statin therapy:an analysis of 20,536 patients in the Heart Protection Study[J].The Lancet,2011,(9764):469-476.